Hagino H, Yoshinaga Y, Hamaya E, Lin TC, Ajmera M, Meyers J. A real-world study of treatment patterns among patients with osteoporotic fracture: analysis of a Japanese hospital database. Arch Osteoporosis. 2023 Jan 23;18(1):23. doi: 10.1007/s11657-022-01201-x
Appukkuttan S, Farej R, Miles L, Purser M, Wen L. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2021 Feb;27(2):166-74. doi: 10.18553/jmcp.2020.20330
Barnett CL, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Montie JE, Denton BT. Two-stage biomarker protocols for early detection of prostate cancer. Med Decis Making. 2017 Oct;37(7):815-26. doi: 10.1177/0272989X17696996
Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478
Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611
Risko R, Merdan S, Womble PR, Barnett C, Ye Z, Linsell SM, Montie JE, Miller DC, Denton BT. Clinical predictors and recommendations for staging computed tomography scan among men with prostate cancer. Urology. 2014 Dec;84(6):1329-34. doi: 10.1016/j.urology.2014.07.051
Merdan S, Womble PR, Miller DC, Barnett C, Ye Z, Linsell SM, Montie JE, Denton BT. Toward better use of bone scans among men with early-stage prostate cancer. Urology. 2014 Oct;84(4):793-8. doi: 10.1016/j.urology.2014.06.010
Goyal RK, Meyer AM, Sheets NC, Federspiel JJ, Carpenter WR, Chen RC, Biddle AK. Cost-utility of proton therapy in the treatment of localized prostate cancer. Poster presented at the 2012 ASCO Annual Meeting I; June 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 May 20; 30(15):e15184.
Kattan MW, Earnshaw SR, McDade CL, Black LK, Andriole GL. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011 Sep 1;9(5):305-15.
Earnshaw SR, Chirila C, McDade CL, Black L, Andriole GL. Cost-effectiveness of dutasteride as a chemoprevention in prostate cancer: rEDUCE within-trial analysis. Presented at the 2011 ISPOR 16th Annual International Meeting; May 2011.
Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.
Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.
Chen L, Candrilli SD. Age-segmented rates of treatment, goal attainment, comorbidities and lifestyle risks among men diagnosed with hypertension and dyslipidemia in the United States. Poster presented at the 2009 Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference; April 2009.
Bell CF, McDade CL, Black L, Earnshaw SR, Kattan MW. Considerations for modeling the cost-effectiveness of preventative prostate cancer treatments. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada.
Earnshaw SR, Pignone M, Tice J, Pletcher M. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Poster presented at the Annual Meeting of the Institute for Operations Research and the Management Sciences; November 2006.
Earnshaw SR, Beard SM, Lynch NO, Cooper A, Cowell W, Middelhoven H. A comparison of the cost-effectiveness of bisphosphonates using persistence data from a UK propsective rct. Poster presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research; September 19, 2006.
Davis KL, Mauskopf J, Chow W, Chao J, Seal B. Titration and persistence with tamsulosin among men with benign prostatic hyperplasia in a large managed care population. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 8, 2006.
Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 Mar 7;144(5):326-36.
Grzywacz JG, Quandt SA, Early J, Tapia J, Graham CN, Arcury TA. Leaving Family for Work: ambivalence and Mental Health Among Mexican Migrant Farmworker Men. J Immigr Minor Health. 2006 Jan 1;8(1):85-97.
Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R, Hebborn A. The impact of persistency on economic models for bisphosphonate therapy in osteoporosis. Poster presented at the 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; March 26, 2005. Rome, Italy.
Talmud PJ, Stephens JW, Hawe E, Demissie S, Cupples LA, Hurel SJ, Humphries SE, Ordovas JM. The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet. 2005;69(6):613-22.
Hawe E, Talmud PJ, Miller GJ, Humphries SE, Northwick Park Heart Study . Second Northwick Park Heart Study. Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genet. 2003;67(Pt 2):97-106.
Dhamrait SS, Payne JR, Li P, Jones A, Toor IS, Cooper JA, Hawe E, Palmen JM, Wootton PT, Miller GT, Humphries SE, Montgomery HE. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J. 2003;24(18):1672-80.
Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet. 2002;66(Pt 2):111-24.
Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost. 2001;85(1):67-74.
Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22(24):2243-52.
Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358(9276):115-9.